Eli Lilly CDR (CAD Hedged)
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 43K
- Market Cap
- $859.4B
- Introduction
Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.
A Study of LY3841136 in Japanese Participants With Obesity or Overweight
- Conditions
- ObesityOverweight
- Interventions
- First Posted Date
- 2024-03-07
- Last Posted Date
- 2025-04-18
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 70
- Registration Number
- NCT06297616
- Locations
- 🇯🇵
P-One Clinic, Hachioji, Tokyo, Japan
🇯🇵Sumida Hospital, Sumida-ku, Tokyo, Japan
🇯🇵Hakata Clinic, Fukuoka, Japan
Effect of Retatrutide Compared With Placebo in Participants With Type 2 Diabetes and Moderate or Severe Renal Impairment, With Inadequate Glycemic Control on Basal Insulin, With or Without Metformin and/or SGLT2 Inhibitor (TRANSCEND-T2D-3)
- First Posted Date
- 2024-03-07
- Last Posted Date
- 2025-04-18
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 320
- Registration Number
- NCT06297603
- Locations
- 🇺🇸
Nephrology Consultants, Huntsville, Alabama, United States
🇺🇸Clinical Research Institute of Arizona (CRI) - Sun City West, Sun City West, Arizona, United States
🇺🇸Kidney & Hypertension Center - Apple Valley, Apple Valley, California, United States
A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)
- Conditions
- Atherosclerotic Cardiovascular Disease (ASCVD)Elevated Lp(a)
- Interventions
- Drug: Placebo
- First Posted Date
- 2024-03-04
- Last Posted Date
- 2025-04-18
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 12500
- Registration Number
- NCT06292013
- Locations
- 🇺🇸
Birmingham Clinical Research, Birmingham, Alabama, United States
🇺🇸Alliance for Multispecialty Research, LLC, Norfolk, Virginia, United States
🇺🇸SEC Clinical Research, Dothan, Alabama, United States
A Study of LY3938577 in Healthy Participants and Participants With Type 1 Diabetes Mellitus (T1DM)
- Conditions
- HealthyType 1 Diabetes Mellitus
- Interventions
- First Posted Date
- 2024-02-28
- Last Posted Date
- 2025-05-06
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 70
- Registration Number
- NCT06280703
- Locations
- 🇩🇪
Profil Institut für Stoffwechselforschung, Neuss, Nordrhein-Westfalen, Germany
A Study of Lebrikizumab (LY3650150) With/Without Topical Corticosteroid Treatment in Participants With Moderate-to-Severe Atopic Dermatitis
- Conditions
- Atopic Dermatitis
- Interventions
- First Posted Date
- 2024-02-28
- Last Posted Date
- 2025-04-20
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 430
- Registration Number
- NCT06280716
- Locations
- 🇨🇳
Wannan Medical College Yijishan Hospital, Wuhu, Anhui, China
🇨🇳China-Japan Friendship Hospital, Beijing, Beijing, China
🇨🇳Peking University People's Hospital, Beijing, Beijing, China
Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor (TRANSCEND-T2D-2)
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2024-02-15
- Last Posted Date
- 2025-04-27
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 1250
- Registration Number
- NCT06260722
- Locations
- 🇺🇸
University of Alabama - Department of Nutrition Sciences, Birmingham, Alabama, United States
🇺🇸Neighborhood Healthcare Institute of Health, Escondido, California, United States
🇺🇸Long Beach Research Institute, Long Beach, California, United States
A Study of Two Different Formulations of Pirtobrutinib (LOXO-305) In Healthy Participants
- First Posted Date
- 2024-02-14
- Last Posted Date
- 2025-01-13
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 28
- Registration Number
- NCT06258174
- Locations
- 🇺🇸
Labcorp Drug Development, Dallas, Texas, United States
A Study to Investigate the Safety and Pharmacokinetics of Lebrikizumab in Healthy Chinese Participants
- First Posted Date
- 2024-02-06
- Last Posted Date
- 2024-06-25
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 24
- Registration Number
- NCT06243198
- Locations
- 🇨🇳
Peking University People's Hospital, Beijing, Beijing, China
A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid Tumors
- Conditions
- Ovarian CancerRecurrent Solid TumorUrinary Bladder NeoplasmEsophageal CancerRenal Pelvis CancerAdvanced Solid TumorProstate CancerMetastatic Solid TumorTriple Negative Breast CancerBladder Cancer
- Interventions
- First Posted Date
- 2024-02-02
- Last Posted Date
- 2025-04-22
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 490
- Registration Number
- NCT06238479
- Locations
- 🇺🇸
AdventHealth Orlando, Orlando, Florida, United States
🇫🇷Institut de cancérologie Strasbourg Europe, Strasbourg, Strasbourg, Alsace, France
🇯🇵National Cancer Center Hospital East, Kashiwa, Chiba, Japan
A Study of LY3537982 in Chinese Participants With Advanced Solid Tumors
- First Posted Date
- 2024-02-01
- Last Posted Date
- 2025-04-18
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 12
- Registration Number
- NCT06235983
- Locations
- 🇨🇳
Jilin Cancer Hospital, Changchun, Jilin, China
🇨🇳The First Affiliated Hospital, Zhejiang University, Hangzhou, Zhejiang, China
🇨🇳Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China